Related references
Note: Only part of the references are listed.Molecular classification of diffuse cerebral WHO grade II/III gliomas using genome- and transcriptome-wide profiling improves stratification of prognostically distinct patient groups
Michael Weller et al.
ACTA NEUROPATHOLOGICA (2015)
Mutational landscape and clonal architecture in grade II and III gliomas
Hiromichi Suzuki et al.
NATURE GENETICS (2015)
Glioma Groups Based on 1p/19q, IDH, and TERT Promoter Mutations in Tumors
Jeanette E. Eckel-Passow et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas
Daniel J. Brat et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Combination genetic signature stratifies lower-grade gliomas better than histological grade
Aden Ka-Yin Chan et al.
ONCOTARGET (2015)
Loss of ATRX, associated with DNA methylation pattern of chromosome end, impacted biological behaviors of astrocytic tumors
Jinquan Cai et al.
ONCOTARGET (2015)
TERT promoter mutations contribute to subset prognostication of lower-grade gliomas
Aden Ka-Yin Chan et al.
MODERN PATHOLOGY (2015)
TERT promoter mutations: a novel independent prognostic factor in primary glioblastomas
Matthias Simon et al.
NEURO-ONCOLOGY (2015)
International Society of Neuropathology-Haarlem Consensus Guidelines for Nervous System Tumor Classification and Grading
David N. Louis et al.
BRAIN PATHOLOGY (2014)
TERT promoter mutations in gliomas, genetic associations and clinico-pathological correlations
M. Labussiere et al.
BRITISH JOURNAL OF CANCER (2014)
RNA-seq of 272 gliomas revealed a novel, recurrent PTPRZ1-MET fusion transcript in secondary glioblastomas
Zhao-Shi Bao et al.
GENOME RESEARCH (2014)
Combined analysis of TERT, EGFR, and IDH status defines distinct prognostic glioblastoma classes
Marianne Labussiere et al.
NEUROLOGY (2014)
Mutations in IDH1, IDH2, and in the TERT promoter define clinically distinct subgroups of adult malignant gliomas
Patrick J. Killela et al.
ONCOTARGET (2014)
ATRX mRNA expression combined with IDH1/2 mutational status and Ki-67 expression refines the molecular classification of astrocytic tumors: evidence from the whole transcriptome sequencing of 169 samples
Jinquan Cai et al.
ONCOTARGET (2014)
TERT promoter mutations in primary and secondary glioblastomas
Naosuke Nonoguchi et al.
ACTA NEUROPATHOLOGICA (2013)
Upregulating mutations in the TERT promoter commonly occur in adult malignant gliomas and are strongly associated with total 1p19q loss
Hideyuki Arita et al.
ACTA NEUROPATHOLOGICA (2013)
Distribution of TERT promoter mutations in pediatric and adult tumors of the nervous system
Christian Koelsche et al.
ACTA NEUROPATHOLOGICA (2013)
TERT promoter mutations in ocular melanoma distinguish between conjunctival and uveal tumours
K. G. Griewank et al.
BRITISH JOURNAL OF CANCER (2013)
The Somatic Genomic Landscape of Glioblastoma
Cameron W. Brennan et al.
CELL (2013)
Frequent Somatic TERT Promoter Mutations in Thyroid Cancer: Higher Prevalence in Advanced Forms of the Disease
Inigo Landa et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2013)
Genetic variants in telomerase-related genes are associated with an older age at diagnosis in glioma patients: evidence for distinct pathways of gliomagenesis
Kyle M. Walsh et al.
NEURO-ONCOLOGY (2013)
TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal
Patrick J. Killela et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
Frequency of TERT promoter mutations in human cancers
Joao Vinagre et al.
NATURE COMMUNICATIONS (2013)
Immune Heterogeneity of Glioblastoma Subtypes: Extrapolation from the Cancer Genome Atlas
Tiffany Doucette et al.
CANCER IMMUNOLOGY RESEARCH (2013)
Frequent ATRX mutations and loss of expression in adult diffuse astrocytic tumors carrying IDH1/IDH2 and TP53 mutations
Xiao-Yang Liu et al.
ACTA NEUROPATHOLOGICA (2012)
Pericyte Depletion Results in Hypoxia-Associated Epithelial-to-Mesenchymal Transition and Metastasis Mediated by Met Signaling Pathway
Vesselina G. Cooke et al.
CANCER CELL (2012)
Clinical and molecular genetic factors affecting postoperative seizure control of 183 Chinese adult patients with low-grade gliomas
G. You et al.
EUROPEAN JOURNAL OF NEUROLOGY (2012)
Molecular prognostic factors of anaplastic oligodendroglial tumors and its relationship: a single institutional review of 77 patients from China
Shouwei Li et al.
NEURO-ONCOLOGY (2012)
Molecular classification of gliomas based on whole genome gene expression: a systematic report of 225 samples from the Chinese Glioma Cooperative Group
Wei Yan et al.
NEURO-ONCOLOGY (2012)
CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 20052009
Therese A. Dolecek et al.
NEURO-ONCOLOGY (2012)
GeneCodis3: a non-redundant and modular enrichment analysis tool for functional genomics
Daniel Tabas-Madrid et al.
NUCLEIC ACIDS RESEARCH (2012)
Correlation of IDH1 Mutation with Clinicopathologic Factors and Prognosis in Primary Glioblastoma: A Report of 118 Patients from China
Wei Yan et al.
PLOS ONE (2012)
Frequent ATRX, CIC, FUBP1 and IDH1 mutations refine the classification of malignant gliomas
Yuchen Jiao et al.
ONCOTARGET (2012)
Identification of MMP-9 specific microRNA expression profile as potential targets of anti-invasion therapy in glioblastoma multiforme
Wei Yan et al.
BRAIN RESEARCH (2011)
Correlation between tumor-related seizures and molecular genetic profile in 103 Chinese patients with low-grade gliomas: A preliminary study
Lei Huang et al.
JOURNAL OF THE NEUROLOGICAL SCIENCES (2011)
Integrated Genomic Analysis Identifies Clinically Relevant Subtypes of Glioblastoma Characterized by Abnormalities in PDGFRA, IDH1, EGFR, and NF1
Roel G. W. Verhaak et al.
CANCER CELL (2010)
MET signalling: principles and functions in development, organ regeneration and cancer
Livio Trusolino et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2010)
Correlation of chromosomes 1p and 19q status and expressions of O6-methylguanine DNA methyltransferase (MGMT), p53 and Ki-67 in diffuse gliomas of World Health Organization (WHO) grades II and III: a clinicopathological study
L. Huang et al.
NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY (2009)
IDH1 and IDH2 Mutations in Gliomas
Hai Yan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
GeneCodis: interpreting gene lists through enrichment analysis and integration of diverse biological information
Ruben Nogales-Cadenas et al.
NUCLEIC ACIDS RESEARCH (2009)
Correlations between molecular profile and tumor location in Chinese patients with oligodendroglial tumors
L. Huang et al.
CLINICAL NEUROLOGY AND NEUROSURGERY (2008)
The 2007 WHO classification of tumours of the central nervous system
David N. Louis et al.
ACTA NEUROPATHOLOGICA (2007)
Evaluation of combination gene therapy with PTEN and antisense hTERT for malignant glioma in vitro and xenografts
Yongping You et al.
CELLULAR AND MOLECULAR LIFE SCIENCES (2007)
Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis
HS Phillips et al.
CANCER CELL (2006)
Long-term efficacy of early versus delayed radiotherapy for low-grade astrocytoma and oligodendroglioma in adults:: the EORTC 22845 randomised trial
MJ van den Bent et al.
LANCET (2005)